The vaccine targets and is internalized by APCs via the surface receptor to enhance antigen presentation and T-cell priming; the resulting HPV16-specific CD8+ T cells then kill HPV16-positive tumor cells via TCR recognition of E6/E7 peptides on MHC I (perforin/granzyme-mediated apoptosis). APCs expressing the receptor are not directly killed.